Clinical Trial Update: FIH, Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal Cancer [Phase 1]

View source ↗

Summary

A first-in-human Phase 1 trial of CC-3, a CD276xCD3 bispecific antibody, is recruiting for colorectal cancer with listed indications including breast cancer, sa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Penile Cancer
• Sarcoma

Drugs mentioned

• CC-3 (CD276xCD3 bispecific antibody)

Snippet

Sponsor: German Cancer Research Center | Conditions: Colorectal Cancer, Breast Carcinoma | Phase 1 | Status: RECRUITING